213 search results for: Pathophysiology
ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP
Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP
The Pathophysiology of Prurigo Nodularis
An infographic exploring the pathophysiology of prurigo nodularis and the role of type 2 inflammation.
A brief overview of the pathophysiology of PN
Dr. Chovatiya explains that PN is primarily a chronic itch disease with a complex pathophysiology involving neuronal changes, type 2 inflammation, and fibrotic skin processes, affecting patients' overall well-being.
The Role of IL-4 and IL-13 in the Pathophysiology of CSU
Dr. Jason Hawkes details the role of IL-4 and IL-13 in the pathophysiology of CSU at EADV 2025
Epidemiology and Pathophysiology of AD in Children
In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses the epidemiology of AD in children and the role of type 2 cytokines in driving the pathophysiology of the disease
Overview of EoE Pathophysiology and the Impact on Patient Burden
Chapter from Interdisciplinary Care of Patients with EoE: Experts Offer Food for Thought video: Focuses on the pathophysiology and burden of EoE
Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE
Learn from Prof. Seema Aceves about the interconnectivity of type 2 inflammation and barrier dysfunction in mediating EoE pathophysiology.
Type 2 Inflammation in EoE and Impact on Disease Burden
Dr. Seema Aceves discusses the role of type 2 inflammation in EoE pathophysiology and disease burden.
Understanding IL-33: A Key Factor in COPD Pathogenesis
Explore the role of interleukin (IL)-33 in chronic obstructive pulmonary disease (COPD) pathophysiology and its potential as a therapeutic target.
ADVENT at CEORL-HNS 2026
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
